MCID: PRP021
MIFTS: 48

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 14
Peripheral Nervous System Neoplasms 42 69
Nerve Sheath Tumors 12 69
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 42
Nerve Sheath Neoplasm 12
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 47 C3321 C4972

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to malignant cardiac peripheral nerve sheath neoplasm and malignant triton tumor, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Apoptosis Modulation and Signaling and Development HGF signaling pathway. The drugs Budesonide and Ipratropium have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and t cells, and related phenotypes are Decreased viability and behavior/neurological

Related Diseases for Peripheral Nervous System Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
id Related Disease Score Top Affiliating Genes
1 malignant cardiac peripheral nerve sheath neoplasm 12.0
2 malignant triton tumor 11.0
3 brain stem astrocytic neoplasm 11.0 NF1 TP53
4 glucocorticoid-induced osteoporosis 11.0 ALK TP53
5 rh isoimmunization 10.9 ENO2 NGF TP53
6 vestibular disease 10.9 ENO2 NF1 TP53
7 autonomic nervous system neoplasm 10.9
8 childhood medulloblastoma 10.9 ENO2 MYCN TP53
9 water-clear cell adenoma 10.9 NGF NTRK1 TP53
10 olfactory neural tumor 10.9 ENO2 NGF TP53
11 neuropathy, hereditary sensory and autonomic, type v 10.9 NGF NTRK1
12 pancreatoblastoma 10.9 ENO2 NF1 TP53
13 cervical adenomyoma 10.9 ENO2 NF1 TP53
14 juxtacortical osteosarcoma 10.9 ENO2 MYC MYCN
15 multiple mucosal neuroma 10.8 CD34 TP53
16 dysgraphia 10.8 CD34 MYC
17 demyelinating disease 10.8 CD34 ENO2 NF1
18 skin hemangioma 10.8 MYC MYCN TP53
19 ovarian lymphoma 10.8 CD34 MYC
20 neurofibroma 10.8 ALK CD34
21 rhizomelic chondrodysplasia punctata, type 3 10.8 CASP3 TP53
22 c-p angle neurinoma 10.8 CD34 NF1 TP53
23 seminal vesicle cystadenoma 10.8 ENO2 MYCN
24 heavy chain disease 10.8 AKT1 ENO2 TP53
25 accelerated tumor formation 10.8 BACE1 CASP3
26 ossifying fibromyxoid tumor 10.8 CD34 ENO2 TP53
27 hypersensitivity reaction type ii disease 10.8 ENO2 MYCN NTRK1 NTRK2
28 febrile seizures, familial, 3b 10.8 NGF NTRK1 NTRK2
29 verruciform xanthoma of skin 10.8 CD34 ENO2
30 primary malignant melanoma of the conjunctiva 10.8 AKT1 CASP3 MYC
31 cavernous hemangioma 10.8 ENO2 MYCN NTRK1 NTRK2
32 integumentary system cancer 10.8 AKT1 CASP3 TP53
33 toxic pneumonitis 10.8 CD34 ENO2 TP53
34 epicardium cancer 10.8 ALK CD34 NF1
35 vulvar keratoacanthoma-like carcinoma 10.8 ENO2 MYC MYCN TP53
36 fallopian tube adenomatoid tumor 10.8 ALK ENO2 MYCN NTRK2
37 pancreatic acinar cell adenocarcinoma 10.8 MFRP NGF PHOX2B
38 rhabdomyosarcoma 2, alveolar 10.8 ENO2 MYCN TH
39 melanotic medulloblastoma 10.8 ENO2 MYC MYCN TP53
40 mediastinum rhabdomyosarcoma 10.8 CD34 ENO2 TP53
41 idiopathic generalized epilepsy 10.7 CASP3 ENO2 NTRK2
42 cowper gland carcinoma 10.7 CD34 TP53
43 peritoneal benign neoplasm 10.7 CD34 ENO2 NF1 TP53
44 non-distal trisomy 10q 10.7 ALK NTRK1 TP53
45 vestibular gland benign neoplasm 10.7 CD34 ENO2 NF1 TP53
46 prostate rhabdomyosarcoma 10.7 ALK ENO2 MYCN TP53
47 benign shuddering attacks 10.7 AKT1 ENO2 TP53
48 medullomyoblastoma 10.7 AKT1 CASP3 MYC TP53
49 trachea squamous cell carcinoma 10.7 AKT1 CASP3 MYC TP53
50 bardet-biedl syndrome 10.6 AKT1 CASP3 MYC TP53

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

GenomeRNAi Phenotypes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.47 AKT1 ALK MYC NF1 NTRK2
2 Decreased viability GR00221-A-2 9.47 AKT1 NF1 NTRK2
3 Decreased viability GR00221-A-3 9.47 AKT1 MYC
4 Decreased viability GR00221-A-4 9.47 AKT1 ALK NF1 NTRK2

MGI Mouse Phenotypes related to Peripheral Nervous System Neoplasm:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 NGF NTRK1 NTRK2 NUMBL PHOX2B TH
2 growth/size/body region MP:0005378 10.46 AKT1 ALK BACE1 CASP3 ENO2 MYC
3 cellular MP:0005384 10.39 AKT1 BACE1 CASP3 CD34 ENO2 MYC
4 nervous system MP:0003631 10.39 AKT1 ALK BACE1 CASP3 CNTN6 ENO2
5 mortality/aging MP:0010768 10.37 NTRK2 NUMBL PHOX2B TH TP53 ALK
6 homeostasis/metabolism MP:0005376 10.35 AKT1 ALK BACE1 CASP3 CD34 MYC
7 integument MP:0010771 10.26 AKT1 ALK BACE1 CASP3 CD34 MYC
8 normal MP:0002873 10.15 AKT1 BACE1 MYC MYCN NF1 NGF
9 muscle MP:0005369 10.13 BACE1 CASP3 MYC MYCN NF1 NGF
10 craniofacial MP:0005382 10.11 NFIC TP53 CASP3 ENO2 MYC MYCN
11 hearing/vestibular/ear MP:0005377 10.09 CASP3 MYC NF1 NTRK1 NTRK2 NUMBL
12 liver/biliary system MP:0005370 10.05 AKT1 MYC MYCN NF1 NTRK2 TH
13 no phenotypic analysis MP:0003012 10.01 BACE1 CASP3 MYC MYCN NGF NTRK1
14 neoplasm MP:0002006 10 TP53 AKT1 ALK CD34 MYC NF1
15 reproductive system MP:0005389 9.91 AKT1 ALK CASP3 MYC MYCN NFIC
16 pigmentation MP:0001186 9.87 ALK CASP3 MFRP MYC NF1 NTRK1
17 respiratory system MP:0005388 9.85 ALK CASP3 ENO2 MYCN NF1 NTRK2
18 skeleton MP:0005390 9.61 AKT1 ALK CASP3 MYC MYCN NF1
19 vision/eye MP:0005391 9.36 ALK CASP3 MFRP MYCN NF1 NGF

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
2
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
3
Terbutaline Approved Phase 4 23031-25-6 5403
4
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
5
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
6
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 437-38-7 3345
8
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 74103-06-3, 66635-83-4 3826
9
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 57-27-2 5288826
10
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2078-54-8 4943
11 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
13
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 137-58-6 3676
14
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
15
Pantoprazole Approved Phase 4 102625-70-7 4679
16
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
17
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
18
Levobupivacaine Approved Phase 4,Phase 2,Phase 3 27262-47-1 92253
19
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
20
Remifentanil Approved Phase 4,Phase 3,Phase 1,Phase 2 132875-61-7 60815
21
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 169590-42-5 2662
22 Parecoxib Approved Phase 4,Phase 3 198470-84-7
23
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
24
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
25
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 170729-80-3 151165 6918365
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
27
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1 172673-20-0 219090
28
Palonosetron Approved, Investigational Phase 4,Phase 3,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
29
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
30
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
31
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
32
Rocuronium Approved Phase 4,Phase 2,Phase 3,Phase 1 119302-91-9, 143558-00-3 441290
33
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
34
Everolimus Approved Phase 4,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
35
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
37
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
38
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
39
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
40
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
41
Adalimumab Approved Phase 4,Phase 2 331731-18-1 16219006
42
Certolizumab pegol Approved Phase 4 428863-50-7
43
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
44
Infliximab Approved Phase 4,Phase 2 170277-31-3
45
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
46
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
47
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
48
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
49
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2 465-65-6 5284596
50
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 3753)

id Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients Unknown status NCT01189409 Phase 4 PEG then Senna;Senna then PEG
3 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4 paracetamol;placebo tablets
4 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
5 Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Unknown status NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
6 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
7 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
8 A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain Unknown status NCT02289261 Phase 4 Morphine;Morphine plus dexmedetomidine
9 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
10 Quadratus Lumborum Block for Percutaneous Nephrostomy Unknown status NCT02121951 Phase 4 MAC
11 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
12 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
13 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4 ketalar
14 Palonosetron Associated to Aprepitant in Prophylaxis of PONV Unknown status NCT02431286 Phase 4 Aprepitant;Placebo;Dexamethasone
15 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
16 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4 profound neuromuscular blockade
17 Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Unknown status NCT00903188 Phase 4 cyclosporine;Everolimus
18 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
19 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
20 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
21 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
22 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
23 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
24 Symptom Management After Breast Cancer Surgery Completed NCT00686127 Phase 4 Lidoderm patch;Placebo patch
25 An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Completed NCT00766831 Phase 4 Hydromorphone
26 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer Completed NCT01006356 Phase 4 Hydromorphone HCl OROS
27 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4 Aprepitant
28 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel anesthesia;periprostatic nerve blockade
29 Chlorhydrate of Ropivacaine and Breast Cancer Surgery Completed NCT00370240 Phase 4 Chlorhydrate de Ropivacaine
30 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
31 Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively Completed NCT02566096 Phase 4 transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
32 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
33 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
34 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
35 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
36 PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain Completed NCT01719757 Phase 4 Oxycodone/Naloxone
37 An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics Completed NCT01060124 Phase 4 Fentanyl D-trans
38 An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain Completed NCT00771199 Phase 4 Transdermal Therapeutic System (TTS)-Fentanyl
39 Wound Infiltration and Breast Cancer Surgery Completed NCT01404377 Phase 4
40 Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology Completed NCT00646945 Phase 4 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar);50% Oxygen/50% Nitrogen premix
41 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
42 Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients Completed NCT01621100 Phase 4 OROS hydromorphone
43 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
44 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
45 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4 0.25% ropivacaine hydrochloride;saline
46 A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain Completed NCT01968018 Phase 4 Tramadol HCI/acetaminophen
47 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
48 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
49 Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective? Completed NCT01317589 Phase 4 fentanyl;methadone
50 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

MalaCards organs/tissues related to Peripheral Nervous System Neoplasm:

39
Prostate, Lung, T Cells, Myeloid, Bone, Brain, Bone Marrow

Publications for Peripheral Nervous System Neoplasm

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 31)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 AKT1 CASP3 MYC NGF NTRK1 TP53
2
Show member pathways
12.74 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
3 12.62 AKT1 CASP3 MYC NTRK1 TP53
4
Show member pathways
12.5 AKT1 ALK CASP3 MYC NF1 NTRK1
5
Show member pathways
12.45 AKT1 CASP3 MYC TP53
6
Show member pathways
12.39 AKT1 CASP3 NTRK1 NTRK2 TP53
7 12.25 AKT1 CASP3 MYC TP53
8 12.19 AKT1 CASP3 MYC NF1 NGF NTRK1
9 12.18 MYC MYCN NTRK1 TP53
10 12.14 AKT1 CASP3 MYC TP53
11 12.12 CASP3 NGF NTRK2 PHOX2B TH
12 12.08 AKT1 CASP3 MYC NF1 TP53
13
Show member pathways
12.08 AKT1 CASP3 MFRP MYC NTRK1 NTRK2
14 12.01 AKT1 CASP3 NGF NTRK1 NTRK2
15
Show member pathways
11.92 AKT1 CASP3 MYC NGF NTRK1 TP53
16 11.9 AKT1 MYC NF1 TP53
17 11.77 AKT1 CASP3 MYC TP53
18 11.74 BACE1 ENO2 MYCN NF1 NGF NTRK1
19 11.68 AKT1 CASP3 TP53
20
Show member pathways
11.66 AKT1 CASP3 NGF TP53
21 11.64 AKT1 MYC NTRK1 TP53
22
Show member pathways
11.59 NGF NTRK1 NTRK2
23 11.51 AKT1 BACE1 CASP3 TP53
24 11.43 BACE1 NTRK1 NTRK2
25 11.41 AKT1 CASP3 MYC TP53
26 11.37 AKT1 CNTN6 MYC MYCN TP53
27 11.33 AKT1 CASP3 MYC TP53
28 11.27 AKT1 CASP3 NGF
29 10.8 CASP3 NTRK2
30
Show member pathways
10.65 NGF NTRK1 NTRK2
31 10.31 MYC MYCN

GO Terms for Peripheral Nervous System Neoplasm

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.93 AKT1 CASP3 NF1 NGF TP53
2 nervous system development GO:0007399 9.93 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
3 protein autophosphorylation GO:0046777 9.86 AKT1 ALK NTRK1 NTRK2
4 neuron differentiation GO:0030182 9.78 CASP3 CNTN6 NTRK2 PHOX2B
5 cerebral cortex development GO:0021987 9.77 NF1 NTRK2 TH
6 cellular response to drug GO:0035690 9.76 MYC TH TP53
7 cellular response to growth factor stimulus GO:0071363 9.74 AKT1 NTRK1 TH
8 negative regulation of neuron death GO:1901215 9.72 AKT1 CD34 NTRK1
9 positive regulation of neuron apoptotic process GO:0043525 9.7 CASP3 NF1 TP53
10 response to nicotine GO:0035094 9.67 CASP3 NTRK1 TH
11 positive regulation of gene expression GO:0010628 9.63 CD34 MYC MYCN NGF NTRK2 TP53
12 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 ALK NGF NTRK1 NTRK2
13 response to gamma radiation GO:0010332 9.61 MYC TP53 TRIM13
14 negative regulation of astrocyte differentiation GO:0048712 9.6 MYCN NF1
15 cellular response to nicotine GO:0071316 9.58 NTRK1 TH
16 negative regulation of fibroblast proliferation GO:0048147 9.58 MYC NF1 TP53
17 phosphatidylinositol-mediated signaling GO:0048015 9.56 AKT1 NGF NTRK1 TP53
18 mechanoreceptor differentiation GO:0042490 9.51 NTRK1 NTRK2
19 neurotrophin signaling pathway GO:0038179 9.37 NTRK1 NTRK2
20 sympathetic nervous system development GO:0048485 9.13 NF1 NTRK1 PHOX2B
21 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 CASP3 NGF NTRK1
22 negative regulation of apoptotic process GO:0043066 10 AKT1 CASP3 MYC NGF TP53

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
2 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
3 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....